Zanubrutinib Drug Asset Due Diligence Report 2026

This Zanubrutinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

251

Registered trials

390

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Zanubrutinib can convert its Small molecule drug profile and BTK biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Zanubrutinib (query alias: zanubrutinib)
Modality / target	Small molecule drug; BTK; BTK inhibitors
Highest global status	Approved
Originator	BeOne Medicines Ltd.
Active developers	BeOne Medicines Ltd., Prelude Therapeutics, Inc., Glenmark Pharmaceuticals Ltd.

The MCP disease footprint includes Plasmablastic Lymphoma, Follicular Lymphoma, Waldenstrom's macroglobulinaemia refractory. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07682415	Phase 2	Not yet recruiting	60	uMRD rate
NCT07674810	Phase 2	Not yet recruiting	40	Safety and Adverse Events (AEs)
NCT07690761	Phase 2	Enrolling by invitation	12	CR

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Th131. BTK Inhibition Resets Pathological B and T Cell Subsets in Patients with IgG4-related Disease

Phase 1; n=10; evaluation: Positive. Reported fields: Glandular volume(24-week) = lacrimal (-45.4% change) and submandibular gland volumes (- 30.0% change, both p < 0.001)

Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma

Phase 1; n=66; evaluation: Positive. Reported fields: ORR(At the RP2D) = 58.0 %

Efficacy and safety of zanubrutinib in Waldenström macroglobulinemia: A systematic review and meta-analysis of clinical trials.

Not Applicable; n=322; evaluation: Positive. Reported fields: AE-associated treatment interruption rate = 10.2 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Zanubrutinib addresses Plasmablastic Lymphoma, Follicular Lymphoma, Waldenstrom's macroglobulinaemia refractory. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 8 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-05-21	Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India	Approved	Financial terms not disclosed
2024-03-28	GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma	Not disclosed	Financial terms not disclosed
2023-05-09	SWIXX AND BEIGENE PARTNER IN 13 COUNTRIES OF CENTRAL AND EASTERN EUROPE, GREECE, CYPRUS AND MALTA	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods for treating sickle cell disease by administering a BTK inhibitor”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO